5 Healthcare Stocks in Focus

Pfizer Inc. (NYSE: PFE) today announced the phase 3 results of investigational compound bosutinib in patients with newly diagnosed chronic myeloid leukemia. The study had a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemia who were treated with bosutinib (39 percent) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26 percent) in the intent-to-treat (ITT) population (p=0.002). The study did not meet its primary endpoint of superior complete cytogenetic response (CCyR) rate at one year versus imatinib (70 percent vs. 68 percent, respectively, [p=0.601]), in the ITT population. Pfizer holds diversified global health care portfolio including human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many consumer health care products. Eli Lilly & Co. (NYSE: LLY) announced in association with Acrux received the FDA approval for breakthrough testosterone drug, Axiron. The Axiron is a  topical solution CIII for testosterone replacement therapy in men. The Axiron is the first testosterone topical solution approved for application via an underarm applicator. This announcement came after Lilly acquired the global licensing rights to Axiron from Acrux for $335 million plus royalties. Eli Lilly is involved in discovery, development, manufacturing and selling pharmaceutical products. Johnson & Johnson (NYSE: JNJ) announced that Janssen Pharmaceutical companies of Johnson & Johnson has a research agreement to collaborate with GE Healthcare to develop non-invasive or minimally invasive diagnostic biosignatures to detect Alzheimer’s disease prior to the onset of clinical symptoms. The pre-symptomatic biosignatures allows earlier diagnosis of the disease and may enable significantly earlier intervention in Alzheimer’s disease. Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the health care field. GlaxoSmithKline plc (ADR) (NYSE: GSK) in association with Valeant Pharmaceuticals International announced receipt of a complete response letter from the U.S. FDA for the New Drug Application for ezogabine, an investigational anti-epileptic drug being studied for the adjunctive treatment of adults with partial-onset seizures. GlaxoSmithKline engages in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter medicines and health-related consumer products. Amgen Inc. (NASDAQ:  AMGN) yesterday announced final results from its 5-year open-label extension study investigating the long-term efficacy and safety of Nplate in adults with chronic immune thrombocytopenic purpura. The Nplate safely and effectively maintained platelet counts in the significant majority of patients for the duration of the study. Amgen is involved in the discovery, development, manufacturing and marketing of medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology.
tdp2664Penny Stock Live